These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 24335351)

  • 21. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.
    Han W; Pan H; Chen Y; Sun J; Wang Y; Li J; Ge W; Feng L; Lin X; Wang X; Wang X; Jin H
    PLoS One; 2011; 6(6):e18691. PubMed ID: 21655094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
    Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
    Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.
    Regales L; Gong Y; Shen R; de Stanchina E; Vivanco I; Goel A; Koutcher JA; Spassova M; Ouerfelli O; Mellinghoff IK; Zakowski MF; Politi KA; Pao W
    J Clin Invest; 2009 Oct; 119(10):3000-10. PubMed ID: 19759520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disruption of the EGFR-SQSTM1 interaction by a stapled peptide suppresses lung cancer via activating autophagy and inhibiting EGFR signaling.
    Yu JJ; Zhou DD; Cui B; Zhang C; Tan FW; Chang S; Li K; Lv XX; Zhang XW; Shang S; Xiang YJ; Chen F; Yu JM; Liu SS; Wang F; Hu ZW; Hua F
    Cancer Lett; 2020 Apr; 474():23-35. PubMed ID: 31931029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells.
    Golding SE; Morgan RN; Adams BR; Hawkins AJ; Povirk LF; Valerie K
    Cancer Biol Ther; 2009 Apr; 8(8):730-8. PubMed ID: 19252415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer.
    Husain H; Scur M; Murtuza A; Bui N; Woodward B; Kurzrock R
    Mol Cancer Ther; 2017 Feb; 16(2):265-272. PubMed ID: 28159915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
    Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
    Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EGFR: An essential receptor tyrosine kinase-regulator of cancer stem cells.
    Talukdar S; Emdad L; Das SK; Fisher PB
    Adv Cancer Res; 2020; 147():161-188. PubMed ID: 32593400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer.
    Liu B; Chen D; Chen S; Saber A; Haisma H
    Biochem Pharmacol; 2020 Aug; 178():114095. PubMed ID: 32535106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Effect of and Mechanism Underlying Autophagy in Hepatocellular Carcinoma Induced by CH12, a Monoclonal Antibody Directed Against Epidermal Growth Factor Receptor Variant III.
    Xu W; Song F; Wang B; Li K; Tian M; Yu M; Pan X; Shi B; Liu J; Gu J; Li Z; Jiang H
    Cell Physiol Biochem; 2018; 46(1):226-237. PubMed ID: 29587298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic targeting of the epidermal growth factor receptor in human cancer.
    Dhomen NS; Mariadason J; Tebbutt N; Scott AM
    Crit Rev Oncog; 2012; 17(1):31-50. PubMed ID: 22471663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR-Signaling and Autophagy: How they Fit in the Cancer Landscape.
    Singh AB
    J Adenocarcinoma; 2016; 1(2):. PubMed ID: 30370422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.
    Tanaka K; Babic I; Nathanson D; Akhavan D; Guo D; Gini B; Dang J; Zhu S; Yang H; De Jesus J; Amzajerdi AN; Zhang Y; Dibble CC; Dan H; Rinkenbaugh A; Yong WH; Vinters HV; Gera JF; Cavenee WK; Cloughesy TF; Manning BD; Baldwin AS; Mischel PS
    Cancer Discov; 2011 Nov; 1(6):524-38. PubMed ID: 22145100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EGFR overexpressing cells and tumors are dependent on autophagy for growth and survival.
    Jutten B; Keulers TG; Schaaf MB; Savelkouls K; Theys J; Span PN; Vooijs MA; Bussink J; Rouschop KM
    Radiother Oncol; 2013 Sep; 108(3):479-83. PubMed ID: 23891088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics.
    Mitchell RA; Luwor RB; Burgess AW
    Exp Cell Res; 2018 Oct; 371(1):1-19. PubMed ID: 30098332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.
    Clark PA; Iida M; Treisman DM; Kalluri H; Ezhilan S; Zorniak M; Wheeler DL; Kuo JS
    Neoplasia; 2012 May; 14(5):420-8. PubMed ID: 22745588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
    Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
    Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stress management by autophagy: Implications for chemoresistance.
    Huang Z; Zhou L; Chen Z; Nice EC; Huang C
    Int J Cancer; 2016 Jul; 139(1):23-32. PubMed ID: 26757106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The quest to overcome resistance to EGFR-targeted therapies in cancer.
    Chong CR; Jänne PA
    Nat Med; 2013 Nov; 19(11):1389-400. PubMed ID: 24202392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
    Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
    Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.